Want to see IN:MANGALAM full AI Analyst Report?
MANGALAM Stock Chart & Stats
₹30.40
-₹1.02(-0.89%)
At close: 4:00 PM EST
₹30.40
-₹1.02(-0.89%)
Day’s Range― - ―
52-Week Range₹22.70 - ₹90.67
Previous CloseN/A
Volume15.57K
Average Volume (3M)5.11K
Market Cap
₹427.84M
Enterprise Value₹1.52B
Total Cash (Recent Filing)₹7.01M
Total Debt (Recent Filing)₹1.05B
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.05
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.42
Price to Sales (P/S)0.19
P/FCF Ratio-2.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Manufacturing Business ModelA focused B2B specialty-chemicals/API intermediates model supplies pharma and chemical firms with inputs that are structurally needed. This creates durable demand from repeat customers, opportunities for contract/custom manufacturing, and longer sales visibility versus consumer markets.
Proven Ability To Be Profitable In Better YearsHistorical profitability demonstrates operational capability and margin potential when volumes or pricing normalize. This suggests management can generate positive EBITDA under supportive market conditions, reducing the risk that current losses are permanent structural failures.
Sizable Asset Base And Positive EquityA meaningful asset base and positive equity provide a balance-sheet cushion to support working capital, negotiate financing, and execute operational turnarounds. These structural resources give the company options to restructure operations or invest selectively to restore cash generation.
Bears Say
Sharp Earnings DeteriorationA dramatic swing to large net losses and negative operating margins indicates core profitability has broken down. Sustained or repeated margin compressions reduce internal funding for capex and R&D, impair pricing power, and increase reliance on external financing to sustain operations over months.
Weak And Inconsistent Cash GenerationNegative operating and free cash flow signal that day-to-day operations are not self-funding, raising structural funding risk. Inconsistent historical cash conversion amplifies this, increasing refinancing and working-capital pressure and constraining the company's ability to invest to regain competitiveness.
Rising Financial LeverageMaterially higher leverage reduces financial flexibility and increases fixed interest obligations. In a capital-intensive manufacturing profile, this limits the ability to fund capacity adjustments or absorb further demand weakness, and magnifies downside during cyclical or demand-driven recoveries.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹90.67 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹427.84M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
Mangalam Drugs & Organics Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on May 14, 2026. The company reported -₹8.48 earnings per share for the quarter, missing the consensus estimate of N/A by -₹8.48.
Is Mangalam Drugs & Organics Ltd. overvalued?
According to Wall Street analysts Mangalam Drugs & Organics Ltd.’s price is currently Overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹8.48 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.311%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mangalam Drugs & Organics Ltd.
Based in Mumbai, India, Mangalam Drugs & Organics Limited, established in 1972, operates as a global pharmaceutical enterprise. The company is engaged in the production and distribution of a diverse range of medications, drugs, and associated pharmaceutical goods, serving both domestic Indian and international markets. Its offerings encompass various active pharmaceutical ingredients (APIs), chemical intermediates, specialized compounds, and impurities, which are crucial for treatments targeting conditions such as malaria, pain and inflammation, high blood pressure, and retroviral infections.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Lasa Supergenerics Ltd.
―
Par Drugs and Chemicals Limited
―
Vaishali Pharma Ltd.
―
Vivimed Labs Limited
―